These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10533890)

  • 1. Safety and efficacy of vigabatrin and carbamazepine. CPMP. The Committee for Proprietary Medicinal Products.
    Elferink AJ; Toivonen M; van Bronswijk H
    Lancet; 1999 Oct; 354(9187):1387-8. PubMed ID: 10533890
    [No Abstract]   [Full Text] [Related]  

  • 2. Another case of reversibility of visual-field defect induced by vigabatrin monotherapy: is young age a favorable factor?
    Giordano L; Valseriati D; Vignoli A; Morescalchi F; Gandolfo E
    Neurol Sci; 2000 Jun; 21(3):185-6. PubMed ID: 11076009
    [No Abstract]   [Full Text] [Related]  

  • 3. Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy.
    Sergott RC; Bittman RM; Christen EM; Sagar SM
    Epilepsy Res; 2010 Dec; 92(2-3):170-6. PubMed ID: 20951555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity.
    Lawthom C; Smith PE; Wild JM
    Ophthalmology; 2009 Mar; 116(3):565-71. PubMed ID: 19168223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group.
    Chadwick D
    Lancet; 1999 Jul; 354(9172):13-9. PubMed ID: 10406359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects.
    Kälviäinen R; Nousiainen I; Mäntyjärvi M; Nikoskelainen E; Partanen J; Partanen K; Riekkinen P
    Neurology; 1999 Sep; 53(5):922-6. PubMed ID: 10496247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversibility of vigabratin-induced visual-field defect.
    Versino M; Veggiotti P
    Lancet; 1999 Aug; 354(9177):486. PubMed ID: 10465180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In utero exposure to vigabatrin: no indication of visual field loss.
    Lawthom C; Smith PE; Wild JM
    Epilepsia; 2009 Feb; 50(2):318-21. PubMed ID: 18616557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Balancing clinical benefits of vigabatrin with its associated risk of vision loss.
    Pellock JM
    Acta Neurol Scand Suppl; 2011; (192):83-91. PubMed ID: 22061183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The function of eye and vision system in children and youth treated with vigabatrin--our own experiences].
    Pojda-Wilczek D; Emich-Widera E; Herba E; Pojda SM; Marszał E
    Klin Oczna; 2005; 107(10-12):654-7. PubMed ID: 16619812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The new antiepileptic drugs.
    Macleod S; Appleton RE
    Arch Dis Child Educ Pract Ed; 2007 Dec; 92(6):182-8. PubMed ID: 18032714
    [No Abstract]   [Full Text] [Related]  

  • 12. Vigabatrin-attributable visual field defects in patients with intractable partial epilepsy.
    Tseng YL; Lan MY; Lai SL; Huang FC; Tsai JJ
    Acta Neurol Taiwan; 2006 Dec; 15(4):244-50. PubMed ID: 17214087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin.
    Ruether K; Pung T; Kellner U; Schmitz B; Hartmann C; Seeliger M
    Arch Ophthalmol; 1998 Jun; 116(6):817-9. PubMed ID: 9639460
    [No Abstract]   [Full Text] [Related]  

  • 14. The ocular side effects of vigabatrin (Sabril): information and guidance for screening.
    Hawker MJ; Astbury NJ
    Eye (Lond); 2008 Sep; 22(9):1097-8. PubMed ID: 18497834
    [No Abstract]   [Full Text] [Related]  

  • 15. Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity.
    Moseng L; Sæter M; Mørch-Johnsen GH; Hoff JM; Gajda A; Brodtkorb E; Midelfart A
    Acta Ophthalmol; 2011 Aug; 89(5):452-8. PubMed ID: 21251242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding and interpreting vision safety issues with vigabatrin therapy.
    Plant GT; Sergott RC
    Acta Neurol Scand Suppl; 2011; (192):57-71. PubMed ID: 22061181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensorineural hearing loss: a reversible effect of vigabatrin.
    Papadeas E; Polychronopoulos P; Papathanasopoulos P; Frimas C; Pharmakakis N; Paschalis C
    Neurology; 2003 Oct; 61(7):1020-1. PubMed ID: 14557592
    [No Abstract]   [Full Text] [Related]  

  • 18. [Vigabatrin and visual fields defects].
    Alving J
    Ugeskr Laeger; 2000 Jan; 162(4):515. PubMed ID: 10697454
    [No Abstract]   [Full Text] [Related]  

  • 19. Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer.
    Wild JM; Robson CR; Jones AL; Cunliffe IA; Smith PE
    Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):917-24. PubMed ID: 16505024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Constriction of the visual field by vigabatrin].
    Asensio Sánchez VM
    An Med Interna; 2002 Dec; 19(12):655-6. PubMed ID: 12593042
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.